Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05620043 · ClinicalTrials.gov registry record · NA
Gene Expression Study Between Two Dermal Injectables Hydroxylapatite Semi-permanent Filler
A NA study, sponsored by Galderma R&D.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT05620043: Completed NA study, sponsored by Galderma R&D.
NCT05620043 is a NA study that has completed, run by Galderma R&D. The registered enrollment target is 21 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05620043, a NA study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
To compare gene expression stimulated by a semi-permanent filler and a biostimulator via punch biopsy
Primary Outcome
Summary of fold change using by relative quantification method at week 12. Gene expression analysis is performed via qPCR processing using a panel of biomarkers related to scar tissue formation, collagen, elastin, extracellular matrix integrity, epidermal barrier, anti-aging, antioxidant, cell renewal/regeneration, inflammation, growth factor, and hydration among others.
Interventions
- DEVICE Sculptra
- DEVICE Radiesse Plus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2022-09-28 |
| Est. Completion | 2023-11-06 |
| Phase | NA |
What the finished NCT05620043 record still lists
NCT05620043 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Sculptra is the first listed.
NCT05620043 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05620043 about?
NCT05620043 is a clinical study titled "Gene Expression Study Between Two Dermal Injectables Hydroxylapatite Semi-permanent Filler". To compare gene expression stimulated by a semi-permanent filler and a biostimulator via punch biopsy
What is the current status of trial NCT05620043?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2022-09-28. Estimated completion is 2023-11-06.
What interventions are being tested in trial NCT05620043?
The interventions under investigation include: Sculptra (DEVICE), Radiesse Plus (DEVICE).
Who is sponsoring clinical trial NCT05620043?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05620043's enrollment target sits among peer trials
21 1762nd of 2000 higher than 233 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI